Clinical evaluation of a rapid A1C test (A1cNow) for home use

Point of Care

Volumn 5, Issue 3, 2006, Pages 116-120

  Klonoff, David C ^a   Bergenstal, Richard M ^b   Cole, Thomas G ^c   Bohannon, Nancy J V ^d   Ammirati, Erika B ^e   Blatt, Joel M ^f   Irvin, Benjamin R ^f   Stivers, Carole R ^f   Clark, Annette L ^f  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e Ammirati Regulatory Consultants   (United States)

^f Metrika Inc   (United States)

Author keywords

AIC; Glycated hemoglobin; Home use; Point of care

Indexed keywords

EID: 33748545946     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/01.poc.0000232578.91019.03     Document Type: Article

References (17)

1. Henry JB. Clinical Diagnosis and Management by Laboratory Methods, 19th ed. Philadelphia, PA: WB Saunders Co; 1996.
2. Nathan DM, Singer DE, Hurxthal K, et al. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341-346.
3. Thaler LM, Dunbar VG, Ziemer DC, et al. Diabetes in urban African-Americans. XVII. Availability of rapid Ale measurements enhances clinical decision making. Diabetes Care. 1999;22:1415-1421.
4. Cagliero E, Levina EV, Nathan DM. Immediate feedback of A1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999;22:1785-1789.
5. Ferenczi A, Kalpana R, Lorber DL. Effect of immediate hemoglobin A1c results on treatment decisions in office practice. Endocr Pract. 2001;7:85-88.
6. Miller CD, Barnes CS, Phillips LS, et al. Rapid Ale availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. 2003;26:1158-1163.
7. Kennedy L, Herman WH, Strange P, et al, GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1-8.
8. Medical Laboratory Observer. Supplement, Point-of-Care Testing; 1992.
9. Lehmann C. The future of home testing - implications for traditional laboratories. Clin Chim Acta. 2002;323:31-36.
10. Health Devices: 32(11); November 2003.
11. Stivers CR, Baddam SR, Clark AL, et al. A miniaturized self-contained single-use disposable quantitative test for hemoglobin A1c in blood at the point of care. Diabetes Technol Ther. 2000;2:517-526.
12. www.ngsp.org.
13. College of American Pathologists GH2-A Glycohemoglobin Participant Summary; 2004.
14. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.
15. Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
16. Delaronde S. Barriers to AIC testing among a managed care population. Diabetes Educ. 2005;31:235-239.
17. Parnes B, Niebauer L, Holcomb S, et al. Provider deferred decisions on hemoglobin Ale results: a report from the Colorado Research Network (CaReNet) and the High Plains Research Network (HPRN). J Am Board Fam Med. 2006;19:20-23.